Edaravone for treatment of early-stage ALS - Authors' reply

Makoto Akimoto¹, Kazue Nakamura²; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group

Affiliations

¹ Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan. Electronic address: akimoto.makoto@mc.mt-pharma.co.jp.
² Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan.

PMID: 28920878
DOI: 10.1016/S1474-4422(17)30290-9

Comment

Edaravone for treatment of early-stage ALS - Authors' reply

Makoto Akimoto et al. Lancet Neurol. 2017 Oct.

. 2017 Oct;16(10):772.

doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12.

Authors

Makoto Akimoto¹, Kazue Nakamura²; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group

Affiliations

¹ Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan. Electronic address: akimoto.makoto@mc.mt-pharma.co.jp.
² Clinical Planning Department I, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo 103-8405, Japan.

PMID: 28920878
DOI: 10.1016/S1474-4422(17)30290-9

No abstract available

PubMed Disclaimer

Comment on

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Writing Group, et al. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. Lancet Neurol. 2017. PMID: 28522181 Clinical Trial.
Edaravone for treatment of early-stage ALS.
Mora JS. Mora JS. Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30289-2. Epub 2017 Sep 12. Lancet Neurol. 2017. PMID: 28920880 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Edaravone for treatment of early-stage ALS - Authors' reply

Affiliations

Edaravone for treatment of early-stage ALS - Authors' reply

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous